$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
新型疗法在晚期宫颈癌中显示出良好活性
2025-10-19 11:44:20
Check Details
调强放疗或成为高风险宫颈癌的新标准疗法
2025-10-19 11:44:20
Check Details
Cemiplimab在宫颈癌3期试验中展示出优异疗效
2025-10-19 11:44:20
Check Details
FDA最新批准:尿路上皮癌、宫颈癌、胆管癌等治疗称号
2025-10-19 11:44:20
Check Details
FDA授予Balstilimab治疗复发性/转移性宫颈癌的优先审查
2025-10-19 11:44:20
Check Details
FDA加速批准Tisotumab Vedotin用于治疗复发或转移性宫颈癌
2025-10-19 11:44:20
Check Details
阿帕替尼能治疗宫颈癌吗?效果好不好?
2025-10-19 11:44:20
Check Details
首款晚期宫颈癌抗体偶联(ADC)药物Tivdak获FDA批准上市
2025-10-19 11:44:20
Check Details
转移性宫颈癌迎来首个抗体偶联药物—Tivdak
2025-10-19 11:44:20
Check Details
转移性宫颈癌首个抗体偶联药物Tivdak获批上市
2025-10-19 11:44:20
Check Details
宫颈癌新药靶向抗体偶联药物Tivdak可诱导持久缓解!
2025-10-19 11:44:20
Check Details
靶向抗体偶联药物(ADC)Tivdak怎么使用?有什么副作用?
2025-10-19 11:44:20
Check Details
1
2
...
221
222
223
224
225
226
227
...
4162
4163
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Zongertinib for HER2-Mutant NSCLC: First-Line ORR About 76%, Brain Metastases Controlled, Manage Diarrhea and Hepatotoxicity
2
Selpercatinib Traditional Approval for RET Fusion Solid Tumors: Weight-Based Adults, BSA-Based Pediatrics, Monitor Liver, BP, QT
3
Atezolizumab Plus mFOLFOX as Adjuvant Therapy for Stage III dMMR Colon Cancer: ATOMIC DFS HR 0.50
4
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance in HER2-Positive Advanced Breast Cancer: HER2CLIMB-05 Median PFS 24.9 Months
5
Zenocutuzumab (Bizengri) for NRG1 Fusion Solid Tumors: HER2×HER3 Bispecific, 750mg Q2W, NSCLC/Pancreas/Cholangiocarcinoma
6
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
7
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
8
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
9
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
10
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
11
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
12
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks